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Aβ42 is known to be a primary amyloidogenic and pathogenic agent in 
Alzheimer’s disease. However, the role of Aβ43, found just as frequently in patient 
brains, remains unresolved. We generated knockin mice containing a pathogenic 
presenilin-1 R278I mutation that causes overproduction of Aβ43. Homozygous 
mice exhibited embryonic lethality, indicating that the mutation involves loss of 
function. Crossing amyloid precursor protein transgenic mice with heterozygous 
mutant mice resulted in elevation of Aβ43 levels, impairment of short-term 
memory, and acceleration of Aβ pathology, accompanying pronounced 
accumulation of Aβ43 in plaque cores similar to the biochemical composition 
observed in patient brains. Consistently, Aβ43 showed a higher propensity to 
aggregate and was more neurotoxic than A42. Other pathogenic presenilin 
mutations also caused overproduction of Aβ43 in a manner correlating with Aβ42 
and with age of disease onset. These findings indicate that Aβ43, an overlooked 
species, is potently amyloidogenic, neurotoxic, and abundant in vivo. 
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Alzheimer’s disease, the most common form of dementia, is characterized by two 
pathological features in the brain, extracellular senile plaques and intracellular 
neurofibrillary tangles. Senile plaques consist of amyloid-β peptide (Aβ) generated 
from amyloid precursor protein (APP) through sequential proteolytic processing by 
β-secretase and γ-secretase. Two major forms of Aβ exist, Aβ40 and Aβ42, with Aβ42
being more neurotoxic due to its higher hydrophobicity, which results in faster 
oligomerization and aggregation1. A number of mutations associated with early-onset 
familial Alzheimer’s disease (FAD) have been identified in the APP, PSEN1 and PSEN2
genes, and these mutations lead to accelerated production of Aβ42 or an increase in the 
Aβ42/Aβ40 ratio. Together these findings indicate that Aβ42 plays an essential role in 
the initiation of pathogenesis. However, the possible involvement of longer Aβ species 
that also exist in Alzheimer’s disease brains has not yet been fully investigated. 
Thus far, various longer Aβ species, such as Aβ43, Aβ45, Aβ48, Aβ49 and Aβ50, 
have been qualitatively described in Alzheimer’s disease brains2. Similar Aβ species 
have also been found in transgenic mice that overexpress APP carrying FAD-linked 
mutations3. Further quantitative studies have revealed that Aβ43 is deposited more 
frequently than Aβ40 in both sporadic Alzheimer’s disease (SAD) and FAD4-7.
How these Aβ species with different C-terminal ends are generated from the 
precursor has mainly been investigated by cell biological and biochemical methods. A 
number of studies8,9 demonstrated that γ/ε-cleavage by γ-secretase activity controls the 
fate of the C-terminal end. Aβ43, generated from Aβ49 via Aβ46, is subsequently 
converted to Aβ40 by γ-secretase whereas Aβ42 is independently generated from Aβ48
via Aβ45. It has also been reported that the FAD-associated I213T mutation in the 
PSEN1 gene increases the generation of longer Aβ species, such as Aβ43, Aβ45 and 
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those even longer than Aβ46, in addition to Aβ4210. It is also noteworthy that Aβ43 
appears to be equally as prone to aggregate in vitro as Aβ4211, leading to faster 
formation of oligomers than occurs in the case of Aβ4012. These observations imply that 
Aβ43 could be produced as a physiological or pathological metabolite of γ-secretase 
activity and may affect Aβ amyloidosis in the brain. 
In order to address whether Aβ43 contributes to Alzheimer’s disease pathology, we 
decided to take advantage of the molecular phenotype of the presenilin-1 (PS1)-R278I 
mutation, as this mutation results in selective overt production of Aβ43 in vitro13, an 
effect which occurs to a much greater extent than in the case of other mutations such as 
R278K, R278S and R278T. The R278I mutation had independently been reported in a 
pedigree suffering from atypical Alzheimer’s disease with language impairment14. A 
follow-up survey revealed that one of the patients subsequently progressed to more 
severe cognitive impairment, and another patient from a different branch of the family 
with the mutation showed Alzheimer’s disease-associated symptoms with an early loss 
of episodic memory and with a clinical onset of the disease at the age of 59 (Rossor 
M.N., personal communication).  
  In this study, we generated PS1-R278I knockin mice to assess the biological 
significance of the mutation and the pathological effect of Aβ43 on Aβ amyloidosis. 
Surprisingly, homozygous knockin mice showed embryonic lethality, presumably due to 
a partial loss of γ-secretase activity resulting in a failure in Notch1 processing. 
Consistent with this, mouse embryonic fibroblasts (MEFs) derived from the 
homozygous knockin mice exhibited a failure in PS1 endoproteolysis and Notch1 
processing, implying that the particular selectivity of the PS1-R278I mutation for Aβ43 
production is closely associated with the partial loss of γ-secretase activity, i.e.
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suppression of the Aβ43-to-Aβ40 conversion, which could also be caused by some of 
the other PS1 mutations. We then demonstrated that heterozygous knockin mice 
crossbred with APP transgenic (Tg) mice exhibit short-term memory loss prior to plaque 
formation and develop considerably accelerated amyloid pathology, establishing that 




Generation of PS1-R278I knockin mice 
To generate PS1 knockin mice, we constructed a targeting vector carrying a point 
mutation that results in amino-acid replacement of R278I in exon 8 of the PSEN1 allele 
(Supplementary Fig. 1a). Homologous recombination, germline transmission and 
genotype were confirmed by Southern blotting and PCR (Supplementary Fig. 1b,c).
The expression levels of the mutant and wild-type PS1 in the embryonic mouse brains 
were identical (Supplementary Fig. 1d). Unexpectedly, homozygous knockin 
(R278I/R278I) mice exhibited embryonic lethality at E15-18 (Fig. 1a). The mutant 
embryos showed an overall size reduction, a stubby tail, limb ateliosis and hemorrhage 
in the central nervous system (CNS) as compared to wild-type (+/+) littermate controls 
(Fig. 1a).
This phenotype is similar to that of PS1-deficient mice and Notch1-related 
mutant mice15,16, although the adverse phenotype of the PS1-R278I knockin animals 
appeared a few days later than that of PS1-deficient mice. In contrast, we observed no 
developmental deficits in heterozygous knockin (+/R278I) mice (Fig. 1a and
Supplementary Fig. 2). The lethal phenotype of the R278I mutation appears to be 
caused by a loss of developmental function that manifests only under the recessive 
condition. In addition, we generated two lines of double mutant mice: R278I 
knockin/PS1 knockout and M146V knockin/PS1 knockout. The former was embryonic 
lethal, the latter normal (Supplementary Fig. 3a-d). This observation suggests the 
characteristic loss-of-function nature of the R278 mutation. To our knowledge, this is 




Abnormal PS1 endoproteolysis and Notch1 processing 
In order to assess the functional significance of the R278I mutation in the PS1 knockin 
line, we analyzed the biochemical properties of PS1-R278I γ-secretase in the embryonic 
brains prior to degeneration (Fig. 1a). Western blotting revealed a dramatic decrease in 
the levels of the N-terminal fragment (NTF) and C-terminal fragment (CTF) of PS1, 
indicating a failure of PS1 endoproteolysis, in the homozygous knockin brains, whereas 
the γ-secretase components, including Nicastrin (Nct), presenilin enhancer-2 (Pen-2) 
and anterior pharynx defective-1 protein (Aph-1), were expressed at normal levels (Fig. 
1b). The NTF and CTF in the homozygous knockin mice were, however, clearly 
detectable, indicating that a fraction of the endoproteolytic activity of PS1 still remained 
(Fig. 1b and Supplementary Fig. 3e). It is also noteworthy that the endoproteolysis 
was partially blocked in the heterozygous PS1-R278I brain, suggesting that the process 
is at least in part autolytic. 
We next investigated whether the PS1-R278I mutation affects the assembly of 
the γ-secretase complex by Blue Native PAGE (BN-PAGE)17. A major signal 
corresponding to a molecular weight of 360 kDa, the normal molecular weight of the 
native PS1 γ-secretase complex, was detected in both the wild-type and knockin brains 
in a manner similar to that of the PS2 γ-secretase complex (Fig. 1c).
Immunoprecipitation experiments further demonstrated that the mutant PS1 formed a 
complex with Nct, Pen-2 and Aph-1 (Fig. 1d). These data indicate that the PS1-R278I 
mutation does not affect the formation of the γ-secretase complex. Interestingly, 
BN-PAGE detected a minor signal corresponding to a higher molecular weight of 750 
kDa in the homozygous knockin brains (Fig. 1c: arrowhead). A similar higher 
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molecular weight signal has previously been described in preparations from a patient 
with a deletion of exon 9 in the PSEN1 gene (PS1-ΔE9)17 and from SH-SY5Y cells 
treated with a γ-secretase inhibitor, L-685,45818. PS1-ΔE9 and PS1-ΔT440 also cause 
PS1 endoproteolytic abnormality in a similar manner to the PS1-R278I mutation19-21.
The presence of this high molecular weight γ-secretase may reflect a conformational 
change in the multi-component complex or binding of additional factor(s) to the 
complex, although its mechanistic involvement remains unclear. 
We then examined the effect of the mutation on the metabolism of the 
γ-secretase substrates. Both the CTF-α and CTF-β of APP and the CTF of N-cadherin 
accumulated at significant levels in the homozygous PS1-R278I knockin mouse brain 
but not in the wild-type or heterozygous brains (Fig. 1e). Conversely, APP intracellular 
domain (AICD) and Notch1 intracellular domain (NICD) could not be detected in the 
homozygous knockin. An additional signal smaller than that of CTF-α appeared in the 
knockin mice (Fig. 1e: asterisk), presumably representing an aberrant proteolytic 
product of CTF-α and β. These data indicate that the PS1-R278I mutation leads to a 
significant loss of γ-secretase activity in a recessive manner. 
In order to further analyze the mutant γ-secretase, we established MEFs from 
knockin mice and littermate controls. Western blotting (Supplementary Fig. 4a),
BN-PAGE (Supplementary Fig. 4b) and Immunoprecipitation experiments 
(Supplementary Fig. 4c) demonstrated that the biochemical properties of mutant PS in 
MEFs were identical to those in the embryonic brains. We then expressed Myc-tagged 
ΔNotch1 in the mutant and wild-type MEFs. Western blot analysis revealed that 
conversion of Myc-ΔNotch1 to Myc-NICD by limited proteolysis takes place in 
wild-type and heterozygous knockin MEFs but not in the homozygous knockin or PS1 
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knockout MEFs (Fig. 1f). These results indicate that the R287I mutation induces 
developmental deficits by abolishing of γ-secretase-dependent Notch1 processing. 
Aβ40, Aβ42 and Aβ43 in PS1-R278I knockin brains and MEFs 
Because homozygous R278I knockin mice are embryonic lethal, we went on to analyze 
adult heterozygous knockin mice. The adult heterozygous mice at 3 and 24 months of 
age were normal in development and anatomy (Supplementary Fig. 2), whereas 
various biochemical properties of PS1, such as partial abnormality of endoproteolysis, 
the molecular weight of γ-secretase and the identity of the complex components, were 
identical to those of the heterozygous embryonic brain (Supplementary Fig. 5). We 
then established a specific and highly sensitive ELISA systems that could distinguish 
between Aβ40, Aβ42 and Aβ43 over a broad concentration range (Fig. 2a,b and 
Supplementary Figs. 6a,b and 7). The antibodies used were highly specific to each 
Aβ species (Fig. 2c-e and Supplementary Fig. 6c-e). Brain tissue fractions soluble in 
Tris-HCl buffered saline (TS) and those that could be dissolved in 6M guanidine-HCl 
(GuHCl) were subjected to quantification. 
There was a significant decrease in the steady state levels of GuHCl-Aβ40 in 
the brains of aged (24-months-old) heterozygous PS1-R278I knockin mice as compared 
to wild-type animals, although no differences were recorded in the levels of TS-Aβs, 
GuHCl-Aβ42 and GuHCl-Aβ43 (Fig. 2f,g). This reduction of GuHCl-Aβ40 resulted in 
a significant elevation of the Aβ42/Aβ40 and Aβ43/Aβ40 ratios in the GuHCl-soluble 
fraction (Fig. 2h,i). Notably, the Aβ43/Aβ42 ratio was also significantly increased in 
the GuHCl-soluble fraction of the heterozygous PS1-R278I knockin mouse brain (Fig.
2j). In younger PS1-R278I knockin mice (3 months old), Aβ43 levels were too low to 
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detect, although the GuHCl-Aβ40 levels were again significantly reduced in the 
knockin mice (Supplementary Fig. 8). These results indicate that Aβ43 levels in the 
mouse brain increase upon aging, and that the increase in the Aβ42/Aβ40 and 
Aβ43/Aβ40 ratios observed in the older heterozygous mice appears to be primarily 
caused by a decrease in Aβ40. Furthermore, the R278I mutation leads to an elevation in 
the Aβ43/Aβ42 ratio in aged mice. Taken together, these findings indicate that the 
PS1-R278I mutation gave rise to a modest in vivo effect in terms of the levels of 
endogenous Aβ species under heterozygous conditions. 
We next quantified the Aβ variants in conditioned medium from knockin MEFs 
(Fig. 2k-n). The steady state levels of Aβ40 were significantly reduced in a 
gene-dose-dependent manner in the PS1-R278I MEFs as compared to wild-type MEFs. 
In contrast, Aβ43 markedly increased in the homozygous knockin MEFs, whereas Aβ42
levels remained unchanged in all genotypes (Fig. 2k). Thus, the ratios of longer 
Aβ species significantly increased in homozygous PS1-R278I knockin MEFs (Fig.
2l-n). Intriguingly, there was no increase in Aβ43 levels in conditioned media from 
heterozygous knockin MEFs (Fig. 2k). To unravel the underlying mechanism, we 
generated heterozygous R278I knockin x PS1 knockout mice (R278I/-) and measured 
the levels of Aβs in conditioned media from cultured MEFs. Indeed Aβ43 levels were 
increased, implying that, in heterozygous PS1-R278I knockin MEFs, wild type PS1 
process Aβ43 to Aβ40 (Fig. 2k). Furthermore, in heterozygous PS1 knockout, no Aβ43
could be detected (data not shown). Together, the data suggests that the γ-secretase 
substrate can be transferred between separate PS1 molecules or between dimmers of 
PS1 as previously suggested22 or even between PS1 molecules within the PS1 
complexes, for further processing. The fact that total Aβ (Aβ40 + Aβ42 + Aβ43) was 
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decreased in heterozygous knockin MEFs, compared to homozygous knockin MEFs, is 
of particular interest. It might be due to a dysfunctional PS1 heterodimer where wild 
type PS1 is either directly affected by PS1-R278I or overloaded with Aβ43 generated by 
PS1-R278I. Further experiments are required to resolve the reason behind the decreased 
total Aβ level (Fig. 2k and Supplementary Fig. 9b). Taken together, the R278I 
mutation inhibits Aβ43 to Aβ40 conversion leading to increased Aβ43 levels and 
concomitant decrease of Aβ40, without altering Aβ42 levels. A similar Aβ-processing
pathway has been previously described by Takami et al9 (Fig. 2k and Supplementary 
Fig. 10).
Aβ pathology and memory impairment of APP Tg mice 
Overexpression of wild-type human APP (hAPPwt) in the above-stated MEFs using a 
semliki-forest virus vector23 resulted in a significant increase in Aβ43 in the 
heterozygous R278I knockin cells (Supplementary Fig. 9). The presence of the 
excessive γ-secretase substrates, i.e. APP CTF-α and β, appears to have forced the 
mutant PS1 to participate in APP processing. These observations prompted us to 
crossbreed heterozygous PS1-R278I knockin mice with APP Tg mice (APP23) to assess 
the effect of Aβ43 in vivo. APP Tg x PS1-R278I knockin mice started to accumulate 
pathological Aβ deposits at around 6 months of age, whereas it took about 12 months 
for single APP-Tg mice to begin to show signs of such deposition (Fig. 3a-d,g,h).
Massive astrocytosis was also detected around the amyloid plaques already at 9 months 
age in the APP Tg x PS1-R278I knockin mice but not in single Tg mice (Fig. 3e,f).
Behaviorally, 3-4 month old APP Tg x PS1-R278I knockin mice exhibited short-term 
memory impairment as compared to single Tg mice when their performance was tested 
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in a Y-maze test (Fig. 3i,j). A similar tendency was also observed in the Morris water 
maze test, although the difference in this case did not reach statistic significance (data 
not shown). Taken together, the above findings indicate that the PS1-R278I mutation 
leads to accelerated Aβ pathology with an accompanying inflammatory response, and 
that the significant cognitive impairment occurs even prior to plaque formation. 
We next quantified the steady state levels of Aβ40, Aβ42 and Aβ43 in the brains 
of APP Tg and APP Tg x PS1-R278I knockin mice at 3 and 9 months. Notably, only the 
double mutant mice exhibited selective elevation of Aβ43 in both TS-soluble and 
GuHCl-extractable brain fractions at 3 months, prior to the pathological deposition of 
Aβ (Fig. 4a-f), but at a time-point when the double mutant mice already showed 
short-term memory impairment (Fig. 3i,j). In contrast, Aβ40 and Aβ42 levels started to 
increase at around 9 months. Consequently, both the Aβ43/Aβ40 and Aβ43/Aβ42 ratios 
were higher in the double-mutant mice than in the single APP Tg mice at both 3 and 9 
months, whereas the Aβ42/Aβ40 ratio remained unaltered (Fig. 4g-i). It is worth noting 
that the elevation of biochemically detectable Aβ43 levels preceded plaque formation, 
implying that Aβ43 may be the initial seeding species and the trigger of memory 
impairment in this mouse model. The steady state level of Aβ43 also increased in an 
age-dependent manner in the single APP Tg mouse brains, beginning prior to the plaque 
formation (Fig. 3g,h and Supplementary Fig. 11).
In addition, we observed that a variety of FAD-associated PS1 mutations resulted 
in overproduction of Aβ43 in a manner correlating with the quantity of Aβ42 as well as 
with the age of onset of the patients24 (Fig. 5 and Supplementary Fig. 12). These 
observations indicate the presence of an intrinsic mechanism by which Aβ43 is 
physiologically generated and that not only Aβ42 but also Aβ43 may be involved in 
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Alzheimer’s disease pathogenesis. The reason for the correlation between Aβ42 and 
Aβ43 remains elusive. 
APP Tg x PS1-R278I versus APP Tg x PS1-M146V knockin mice 
We also made another line of double-mutant mice by crossbreeding the APP Tg mice 
with PS1-M146V knockin mice as a positive control with which to compare the APP Tg 
x PS1-R278I knockin mice, given that the former mutation results in overproduction of 
Aβ42 rather than Aβ4325 As expected, the PS1-M146V mutation, unlike the PS1-R278I 
mutation, resulted in selective accumulation of Aβ42 (Supplementary Fig. 13).
Although the steady state levels of Aβ42 in the APP Tg x PS1-M146V mice was about 
10-fold greater than that of Aβ43 in APP-Tg x PS1-R287I mice at 9 months, the total 
plaque areas, as determined by immunohistochemistry, were similar (Fig. 6). Both 
double-mutant lines accumulated Aβ40 and Aβ42, whereas Aβ43 occurred much more 
abundantly in the APP Tg x PS1-R278I mice (Fig. 6a,b). Quantitative image analyses 
gave consistent results (Fig. 6c-e). Aβ43 immunoreactivity colocalized with the plaque 
cores in a manner similar to that of Aβ42 but not Aβ40 (Fig. 6f-h). Interestingly, Aβ
species with the 3rd N-terminal residue converted to pyroglutamate (N3pE-Aβ), a 
potently pathogenic Aβ subspecies26-29, also colocalized with plaque cores and 
deposited more abundantly in APP Tg x PS1-R278I mice than in APP Tg x PS1-M146V 
animals (Supplementary Fig. 14). Although the underlying mechanism that accounts 
for the elevated N3pE-Aβ generation in the APP Tg x PS1-R278I mice remains unclear, 
the observation is consistent with a previous report that some presenilin mutations 
increase the quantity of N-terminally truncated Aβ in the brains of FAD patients30.
Although APP Tg x PS1-M146V mice accumulated greater numbers of Aβ
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plaques in the cortical and hippocampal areas than APP Tg x PS1-R278I mice, the 
density of thioflavin S-positive plaques per total plaques was significantly greater in the 
APP Tg x PS1-R278I knockin mice (Fig. 7a-f). This observation indicates that Aβ43 is 
even more prone to seed cores in plaque formation than Aβ42. To test this hypothesis in
vitro, we performed thioflavin T binding experiments using an equal amount of Aβ40,
Aβ42 and Aβ43 (20 μM each). Aβ43 induced the highest incorporation of thioflavin T 
into Aβ aggregates (Fig. 7g). In addition, stoichiometric experiments, in which we 
added a relatively small quantity of Aβ40, Aβ42 or Aβ43 (0.2 μM) to a mixture of Aβ40
(20 μM) and Aβ42 (2 μM), also showed that Aβ43 most potently accelerated 
incorporation of thioflavin T (Fig. 7h). These indicate that Aβ43 contributes to the 
formation of the thioflavin T-positive β-sheeted structure to a greater extent than either 
Aβ40 or Aβ42, a finding that may account for the observation that a relatively small 
amount of Aβ43 is sufficient to accelerate Aβ amyloidosis and induce plaque core 
formation in vivo.
Neural toxicity and amyloid pathology of Aβ43
In agreement with Aβ42 having higher hydrophobicity and higher toxicity than Aβ40 in
vitro and in vivo, a large number of reports also show that Aβ42 contributes to synaptic 
dysfunctions31-34. Herein, we compared the toxicity of Aβ40, Aβ42 and Aβ43. Aβ43
and showed a higher potent neural toxicity in a dose-dependent manner as compared to 
Aβ40 and Aβ42 (Fig. 7i,j). These results anticipate that Aβ43 directly affects neural 
toxicity and induces synaptic dysfunction, which would contribute to short-term 
memory impairments prior to the amyloidogenesis (Fig. 3i.j).
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Finally, we performed immunohistochemical experiments on brain sections 
from SAD patients to explore the possible involvement and significance of Aβ43 in 
human neuropathology. Aβ43 accumulated in the brains more frequently than Aβ40
(Fig. 8a-e and Supplementary Fig. 15), and was present in both diffuse (Fig. 8f,g)
and dense-cored (Fig. 8h,i) plaques, similar to Aβ42 and N3pE-Aβ (Supplementary 
Fig. 16a-d). Furthermore, thioflavin S fluorescence signals colocalized well with Aβ43 
immunoreactivity (Fig. 8j-m), as well as with N3pE-Aβ (Supplementary Fig. 16e-g). 
These observations are consistent with those of previous studies showing that a 




Previous studies have elegantly demonstrated that Aβ42 is essential for amyloid 
deposition in vivo31 and that Aβ40 inhibits this deposition32, based on the use of Bri-Aβ
fusion proteins. The difference between Aβ40 and Aβ42 lies in the carboxyl-terminal 
amino-acid sequence, i.e. the additional presence of isoleucine and alanine residues in 
Aβ42. Because both isoleucine and alanine are hydrophobic amino acids, it is 
reasonable to assume that Aβ42 is more prone to form a β-sheet structure than Aβ40. In 
contrast, the carboxyl-terminal amino acid of Aβ43 is threonine, which carries a 
hydrophilic alcohol group (together with a hydrophobic methyl group) and thus could 
reverse the hydrophobicity of Aβ42. Therefore, the amyloidogenicity of Aβ43, a natural 
product of γ-secretase activity8,9, has remained elusive. 
Herein, we focused on Aβ43, an overlooked species in AD research, to 
investigate a crucial role in amyloidogenesis and pathogenesis of AD. So far, the major 
focus has been placed on the amyloidogenecity of Aβ42 and in numerous studies; BC05, 
an anti-Aβ42 antibody has been used to demonstrate that Aβ42 is the major pathogenic 
species in AD. Since partial crossreactivity of BC05 against to Aβ43 had already been 
reported47, Aβ42(43), like this orthography, was noted in some of the carefully designed 
and interpreted studies using BC05, as a tacit understanding. However, many of other 
studies apparently overestimated the Aβ42 levels and ignored the possible changes in 
Aβ43 levels. Almost all FAD-associated PS1 mutations result in an increase of the 
Aβ42/Aβ40 ratio caused by an increase of Aβ42 levels. However, some of the PS1 
mutations lead to a decrease of Aβ40 with or without alteration of Aβ42 levels which 
also leads to an increase of the Aβ42/Aβ40 ratio. One explanation of the association 
between decreased Aβ40 and FAD could possibly be that Aβ40 plays a role in 
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protection from plaque fromation32. We here report that in PS1-R278I knockin mice, 
Aβ40 levels are decreased accompanying increased levels of Aβ43. Furthermore, the 
increased Aβ43 levels accelerated Aβ pathology, thus contributing to the early onset of 
the disease. Therefore, we propose that Aβ43 be separately analyzed apart 
from Aβ42.
In an effort to explore the role of Aβ43 in Aβ amyloidosis, we generated 
PS1-R278I knockin mice based on the knowledge that this mutation causes 
overproduction of Aβ43 in vitro13. We chose to use this PS mutation knockin paradigm 
rather than the overexpression strategy for the following reasons. First, the R278I 
mutation is known to be clinically pathogenic. The knockin paradigm is also less 
artificial than Tg overexpression approaches in general, and we considered that the 
knockin mice could potentially be utilized to generate a relevant AD model by 
crossbreeding with other mice such as mutant APP Tg or knockin mice. Unexpectedly, 
the phenotype of the homozygous knockin mice proved to be embryonic lethal in 
association with abnormal PS1 endoproteolysis. Limited proteolysis of APP CTF-α,
CTF-β, N-cadherin and Notch1 was also hampered in the homozygous knockin 
embryos, although the γ-secretase components appeared to have been properly 
assembled to a 360 kDa complex. Based on previous studies, it appears that the 
disturbance in Notch1 processing represents the primary cause of the premature death 
that we observed16,35. Compared to PS1 knockout, the embryonic lethality of PS1-R278I 
knockin mice occurs at a slightly later stage. Taking into account that a 50 % reduction 
of γ-secretase activity in heterozygous PS1-R278I or in heterozygous PS1 knockout 
does not lead to embryonic lethality while the 90% reduction in homozygous 
PS1-R278I does so, it seems that the γ-secretase activity threshold for survival is 
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somewhere between 10-50 % of wild type. The remaining 10% γ-secretase activity in 
homozygous PS1-R278I knockin could account for the delayed lethality compared to 
PS1 knockout (Supplementary Fig. 10c). Taken together, these results strongly 
suggested that the primary phenotype of the R278I mutation was a partial loss of 
function in terms of γ-secretase activity. 
Despite this, MEFs prepared from homozygous embryos produced an 
extremely large steady state levels of Aβ43 (approximately 20-fold greater than that of 
wild-type MEFs); this accompanied a significant decrease in Aβ40 production and no 
changes in Aβ42 levels. Previous in vitro studies have also demonstrated that Aβ43 is 
processed to Aβ40 whereas Aβ42 is independently produced from Aβ45 in the presence 
of γ-secretase8,9. In agreement with these studies, our results from crossbreeding 
heterozygous PS1-R278I mice with PS1 knockout mice, which showed significant 
levels of both Aβ40 and Aβ43, indicated that Aβ43 was indeed converted to Aβ40
independently of Aβ42 production (Fig. 2k). Furthermore, we found that the ratio of 
production of Aβ46 in homozygous PS1-R278I MEFs was increased with a 
concomitant increase of Aβ43 and decrease of Aβ40 in in vitro γ-secretase assays 
(Supplementary Fig. 10), suggesting that production of Aβ40 and Aβ43 also depends 
on Aβ46 production as previously postulated8-10. Thus, inhibition of this Aβ43-to-Aβ40 
conversion could account for the increase in Aβ43 and the concomitant decrease in 
Aβ40 in the knockin MEFs. Interestingly, treatment of PS1-ΔE9-expressing cells with 
L-685,458 resulted in elevated Aβ43 production36, consistent with the notion that 
multiple processes are involved in the generation of various Aβ species and that a 
partial loss of γ-secretase activity might give rise to a particular Aβ species. However, in
vitro γ-secretase activity of heterozygous and homozygous PS1-R278I was drastically 
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reduced in a gene-dose-dependent manner, while there were no significant differences 
of the steady state levels of total MEF-produced Aβ compared to wild type MEFs. To 
elucidate the reason behind this contradiction, it will be necessary to investigate other 
mechanisms e.g. intracellular trafficking and secretion of Aβ in depth. 
The molecular mechanism that allows Aβ43 production but not other 
proteolytic processes remains to be clarified, but it is likely to involve specific 
conformational changes of the γ-secretase complex37. Because Aβ42 is produced 
independently of Aβ43 in the presence of γ-secretase, some of the FAD-associated PS1 
mutations that cause a decrease in Aβ40 without an increase in Aβ42, such as A79V, 
A231V, C263F, L282V, L166P and G384A24,38, might actually result in the elevation of 
Aβ43 in a manner similar to the R278I mutation. In addition, PS1-ΔE10, an artificial 
PS1 mutation located to the loop domain of PS1 where R278I is present, showed a 
significant reduction of the steady state levels of Aβ40 without any alteration of the 
Aβ42 levels similar to our results, however Aβ43 levels were not measured39. It will 
therefore be important to investigate if these FAD-associated mutations give rise to 
increased Aβ43 levels and importantly, scrutinize their amyloidogenicity. In fact, I143T, 
L262F, L282V and G384A mutations did lead to significant production of Aβ43 in our 
transfection assays. Notably, Aβ43 levels and the ratio of Aβ43/Aβ40 significantly 
correlated well with the age of disease onset in a manner similar to Aβ42 levels and the 
ratio of Aβ42/Aβ40. Additionally, a PS1-I143T carrier in a Swedish family with FAD 
gave rise to high levels of Aβ437. These observations highlighted the possibility that 
compounds that facilitate the Aβ43-to-Aβ40 and Aβ42-to-Aβ38 conversion might be 
beneficial for prevention and treatment of AD by decreasing not only Aβ42 but also 
Aβ43. In support of this notion, an oral vaccination with adeno-associated virus vector 
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carrying Aβ1-43 cDNA was reported to result in a marked reduction of Aβ burdens and 
improvement of behavioral performances in APP transgenic mice40,41.
Although our original plan had been to establish APP Tg x homozygous 
PS1-R278I knockin mice, we also explored the possible utility of heterozygous 
PS1-R278I knockin mice, given that overexpression of APP in heterozygous PS1-R278I 
knockin MEFs resulted in selective elevation of Aβ43. Consistent with this, APP Tg x 
heterozygous PS1-R278I knockin mice exhibited short-term memory impairment, 
selective biochemical accumulation of Aβ43 at an early stage prior to plaque formation 
and significant acceleration of Aβ pathology thereafter as compared to single APP Tg 
mice. It is also important to note that the APP Tg x PS1-R278I knockin mice exhibited a 
greater density of the thioflavin S-positive signal per plaque than APP Tg x PS1-M146V 
knockin mice, which overproduce Aβ42 instead of Aβ43. Consistent with previous 
reports6,7, we have observed Aβ43-positive plaques more often than Aβ40-positive ones 
in AD brains. Aβ43 has previously been found in amyloid plaques not only in AD 
patients4,6,7 but also in aged gorillas42 and in some AD model mice harboring PS1 or 
APP FAD-mutations3,10. In addition, it has been suggested that the amount of Aβ43 in 
plaques correlates with cognitive decline5. We also showed in this report that Aβ43 
exhibited potent neural toxicity, comparable to or even greater than that of Aβ42. These 
observations establish that Aβ43 is indeed amyloidogenic in vivo and likely to be 
pathogenic. Thus, the carboxyl-terminal amino acid residue of Aβ43, i.e. threonine, 
appears to strengthen the hydrophobicity of the peptide rather than reversing it. 
Notably, biochemical accumulation of Aβ43 preceded pathological deposition 
in the APP Tg x PS1-R278I knockin mice and in the single APP Tg mice. In addition, 
the basal Aβ43 levels substantially increased with aging in wild-type mice up to at least 
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18 months of age (data not shown). These observations point to the possible value of 
Aβ43 as a biomarker for presymptomatic diagnosis of AD. We therefore believe that it 
would be worth trying to quantify Aβ43 levels in cerebrospinal fluid from AD patients 
and controls although this is beyond the scope of the present study. We also detected the 
presence of N3pE-Aβ in APP Tg x PS1-R278I knockin mouse brains, a finding that is 
supported by a report quantitatively describing N3pE-Aβ42 and N3pE-Aβ43 in the 
brains of FAD and SAD patients2. It is of particular interest that Pittsburgh Compound 
B, a probe for amyloid imaging by positron emission tomography, selectively binds to 
N3pE-Aβ26, implying that N3pE-Aβ42/43 could be particularly prone to seed 
deposition of other Aβ species, consistent with previous reports28. It is also possible that 
the mutation might affect the interaction of PS1 with other substrates or alter its 
property of non-γ-secretase activity29.
In summary, our observations establish that Aβ43, which has to large extent 
been overlooked, is potently amyloidogenic and toxic and highlight the potential value 
of Aβ43, i.e. CSF Aβ43 levels, as an early marker for some of the detrimental effects of 
aging in the adult brain. We propose that inhibition of Aβ43 generation, for instance, by 
facilitating the conversion of Aβ43 to Aβ40 in the γ-secretase complex should be 
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Figure 1. Phenotypic and biochemical characterization of PS1-R278I knockin 
mice.
(a) Embryonic lethality of homozygous PS1-R278I knockin mice. An overall size 
reduction, stubby tail (arrowheads), limb ateliosis (yellow arrows) and hemorrhage in 
the CNS (arrows) were observed. Scale bars: 2 mm. (b-e) Embryonic brains and (f)
MEFs were subjected to Western blot analyses (see Supplementary Fig. 4 for more 
information). Antibodies used are listed on the left side of each panel. (b) Expression of 
γ-secretase components. FL: full-length PS1. (c) BN-PAGE analysis of native 
γ-secretase complexes. The symbol (-/-) is used for the homozygous PS1 knockout 
mice used as a negative control. Arrows indicate the position of the native wild-type 
360 kDa PS1 and PS2 γ-secretase complexes, whereas arrowheads point to the atypical 
high molecular weight (750 kDa) γ-secretase complex. (d) Immunoprecipitation by 
antibodies to PS1-NTF. IgG(H) and IgG(L) indicate immunoglobulin heavy and light 
chains, respectively. (e) γ-secretase activity in PS1-R278I knockin brains. Brain extracts 
were analyzed by Western blotting to detect endogenous APP-CTF-β, APP-CTF-α,
AICD, full-length N-cadherin, N-cadherin-CTF and NICD products. (f)
Notch1-processing in PS1-R278I knockin MEFs. Myc-tagged ΔNotch was transiently 
expressed in the MEFs, and cell lysates were subjected to Western blot analysis using 
anti-Myc antibody. β-actin levels are shown as internal controls. 
Figure 2. Aβ levels in adult PS1-R278I knockin mouse brains and MEFs. 
(a,b) Establishment of ELISA system to specifically quantify Aβ42 and Aβ43 (see more 
Supplementary Figs 6a,b and 7). (c-e) Specificity of the antibodies to Aβ40, Aβ42
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and Aβ43 used in this ELISA system. Synthetic Aβ1-40, Aβ1-42 and Aβ1-43 were 
separated by Tris/Tricine PAGE (15% polyacrylamide gel) and subjected to Western 
blotting. Anti-Aβ antibodies, C40, C42 and C43, specifically recognized the Aβs, 
respectively (see more Supplementary Fig. 6c-e). (f-n) Quantification of Aβ40, Aβ42
and Aβ43 by ELISA in adult mouse brains (f-j) and MEFs (k-n). (f-j) Cortical 
hemispheres from 24 month old wild-type and heterozygous knockin mice were 
homogenized and fractionated into TS-soluble and GuHCl-soluble fractions. Data 
represent mean ± s.e.m. (n = 9). *P < 0.05 and **P < 0.01 between wild type and 
heterozygous knockin mice; Student-t test. (k-n) Aβ concentrations in conditioned 
medium from MEFs. 8x105 cells were inoculated in a 1 ml culture. The conditioned 
medium was collected after 24 hrs and subjected to ELISA. The symbol (R278I/-) is 
used for the double heterozygote of PS1-R278I knockin crossbred with PS1 knockout 
mice. Data represent mean ± s.d. from two independent experiments (n = 16). **P < 
0.01 compared with wild type; One-way ANOVA with Scheffe’s F test.
Figure 3. Acceleration of Aβ pathology and short-term memory impairment by the 
R278I knockin mutation in APP Tg mice. 
(a-f) Brain sections from APP Tg x PS1-R278I knockin mice (a: 3- , b: 6- , and c, e:
9-month old) and 9-month old single APP Tg mice (d,f) were immunostained with 4G8 
anti-Aβ antibody (a-d) and anti-GFAP antibody (green) with 4G8 counterstaining (red) 
(e,f). Aβ immunostained brain sections from cortex (g) and hippocampus (h) of 3-, 6-, 
9- and 12-month old wild-type, APP Tg, and heterozygous PS1-R278I knockin mice, as 
well as APP Tg x PS1-R278I knockin mice were analyzed (n = 5-6 each genotype); *P
< 0.05 and **P < 0.01 compared with APP Tg mice; Two-way ANOVA with Scheffe’s F 
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test. Scale bars: 500 μm (a-d); 50 μm (e,f). (i,j) Y-maze test was performed prior to 
plaque formation using 3-4 month old male wild-type, PS1-R278I knockin, APP Tg 
and APP Tg x PS1-R278I knockin mice. Data represent mean ± s.e.m. (n = 10 each 
genotype), *P < 0.05 compared with wild type or PS1-R278I knockin mice; One-way 
ANOVA with Scheffe’s F test.
Figure 4 Aβ40, Aβ42 and Aβ43 in APP Tg x PS1-R278I knockin mice.
(a,d) The levels of Aβ40, (b,e) Aβ42 and (c,f) Aβ43 were quantified by ELISA and (g-i)
the ratios of the Aβ species were subsequently determined. Cortical hemispheres from 
single APP Tg and APP Tg x PS1-R278I knockin mouse brain (3 and 9 month old) were 
homogenized and fractionated into TS-soluble fractions (a-c) and GuHCl-extractable 
fractions (d-f). Data represent mean ± s.e.m. (n = 7: 3 months old; n = 5: 9 months 
old); *P < 0.05 and **P < 0.01 between APP Tg mice and APP Tg x PS1-R278I 
knockin mice; Student-t test. 
Figure 5. Effect of various pathogenic PS1 mutations on Aβ43 production.
The constructs containing PSEN1 with FAD-associated mutations were transfected into 
HEK293 cells stably expressing APP with the Swedish mutation: (a) Expression levels 
of PS1-FAD mutants. (b-g) Quantification of the steady state levels of Aβ40, Aβ42 and 
Aβ43 and the correlation between Aβ levels and the age of disease onset. Age of onset 
is shown as follows: wild type (75 years old), A79V (59.3), V94M (53), I143T (32.5), 
A231V (58), L262F (50.3), L282V (44) and G384A (34.9)24,50. Data represent mean ± 
s.d. from five independent series each consisting of duplicate measurements; *P < 0.05 
and **P < 0.01 compared with wild type; One-way ANOVA with Dunnett test. 
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Figure 6. Localization of Aβ species in amyloid plaques of APP Tg x PS1-R278I 
knockin mice. 
(a) A set of serial brain sections from 9 month old APP Tg x PS1-M146V knockin mice 
and (b) APP Tg x PS1-R278I knockin mice were immunostained with the following 
anti-Aβ antibodies as indicated: 4G8 (total Aβ), C40 (Aβx-40), C42 (Aβx-42) and 
C43 (Aβx-43). (c-e) The immunoreactive areas in single APP Tg (left column), APP 
Tg x PS1-M146V knockin (middle column) and APP Tg x PS1-R278I knockin (right 
column) mice were quantified as indicated (n = 6); **P < 0.01 between APP Tg x 
PS1-M146V knockin mice and APP Tg x PS1-R278I knockin mice; One-way ANOVA 
with Scheffe’s F test. N.D.: not detected. (f-h) Double-staining with 4G8 (green) and 
the following Aβ species-specific antibodies (red): Aβ40 (f), Aβ42 (g) and Aβ43 (h).
The images in the left (green) and middle (red) are merged (yellow) in panels on the 
right. Scale bars: 500 μm (a,b); 50 μm (f-h).
Figure 7. Mature amyloid plaques in APP Tg x PS1-R278I knockin mice and in
vitro aggregation property and neural cell toxicity of Aβ43. 
(a-f) A set of serial brain sections from 9 month old APP Tg x PS1-M146V knockin 
mice (a,c) and APP Tg x PS1-R278I knockin mice (b,d) were stained with thioflavin S 
(a,b) and immunostained with 4G8 (c,d). Thioflavin S positive plaque are marked with 
arrows (a,b) and the corresponding plaques in the serial brain sections are also marked 
(c,d), respectively. Scale bars: 500 μm (a-d). Intensity of cortical and hippocampal Aβ
immunoreactivity and thioflavin S signals were quantified (e), and the ratio of thioflavin 
S/total Aβ signal of amyloid plaques was determined (f) (n = 12); **P < 0.01 between 
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APP Tg x PS1-M146V knockin mice and APP Tg x PS1-R278I knockin mice; Student-t 
test. (g,h) In vitro Aβ aggregation experiments. Incorporation of thioflavin T into Aβ
aggregates was measured by fluorescence spectroscopy. (g) The aggregation property of 
20 μM Aβ40, Aβ42 and Aβ43 at 20 μM was measured individually. (h) The effect of 
Aβ40, Aβ42 and Aβ43 at a concentration of 0.2 μM on the mixture of 20 μM Aβ40 and 
2 μM Aβ42 was then assessed. Data represent mean ± s.d. from three independent series 
each consisting of 6-8 individual measurements; **P < 0.01 (g) between Aβ40 and 
Aβ42 or between Aβ42 and Aβ43, #P < 0.05 (h) between Aβ40 and Aβ43; One-way 
ANOVA with Scheffe’s F test. (i,j) Neural cell toxicity of Aβ43. Cell viability (i) and 
LDH release as a measure of cell toxicity (j) were assayed. Aβs were administrated at 1, 
3 and 10 μM, respectively. The results obtained after treatment with Aβ40 (open 
column), Aβ42 (gray column) and Aβ43 (filled column) are indicated, and vehicle (veh) 
treatment was also indicated by open column in (j). Data represent mean ± s.d. from 
three independent series each consisting of 6 individual measurements; *P < 0.05 and 
**P < 0.01 between Aβ40 and Aβ42 or between Aβ42 and Aβ43, and #P < 0.05 
between Aβ40 and Aβ43; Two-way ANOVA with Scheffe’s F test or Dunnett test.
Figure 8. Aβ43 in amyloid plaques in AD brains. 
(a-d,f-i) Serial sections of the hippocampal region (a-d, h,i and j-m) and the frontal 
cortical region of AD brains (f,g) were stained with the anti-Aβ antibodies 4G8 (total 
Aβ), C40 (Aβx-40), C42 (Aβx-42), and C43 (Aβx-43), as well as thioflavin S, as 
indicated. The single staining (a-d,f-i) was developed using 3,3’-diaminobenzidine, 
whereas the double-staining (j-m) utilized the fluorescent dyes fluorescein (green, Aβ)
and rhodamine (red, Aβ43). The images in panels (j) and (k) are merged (yellow) in 
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panel (l). Scale bars: 250 μm (a-d); 25 μm (f-m). (e) Ratio of Aβ40, Aβ42 and Aβ43
of the plaque areas in the hippocampal region of AD brain sections from 4 individuals 
were quantified; **P < 0.01 between Aβ40 and Aβ43; One-way ANOVA with Scheffe’s 




Generation of PS1-R278I knockin mice 
As shown in Supplementary Fig. 1, the genomic DNA of mouse PSEN1 was isolated 
from the bacterial artificial chromosome (BAC) library from the 129/Sv mouse genome, 
and one BAC clone which included intron 5 to intron 11 of the PSEN1 gene was 
obtained. The fragment from the ApaI site of intron 5 to the HindIII site of intron 11 
provided the basis for construction of the targeting vector. To introduce the PS1-R278I 
mutation, the SmaI/BamHI fragment containing introns 7 and 8 of the PSEN1 gene was 
subcloned into pBluescript vector. To introduce the R278I mutation the following 
primer was used (underlined: original G to T), 
5’-GGTTGAAACAGCTCAGGAAATAAATGAGACTCTCTTTCCAGC-3’, using 
GeneEditor Mutagenesis System (Promega) according to the manufacturer’s protocol. 
This fragment was used to replace the original sequence of the PSEN1 gene. Finally, a 
pgk-neo gene cassette was inserted for positive selection at the EcoRI/SmaI sites located 
in intron 7, and a Diphtheria toxin-A fragment cassette was inserted for negative 
selection at the HindIII site in intron 11. We used the fragment of ApaI/EcoRI spanning 
from intron 5 to intron 7 (4.3kbp) as the long arm and the fragment of BamHI/HindIII 
spanning from intron 8 to intron 11 (3.8kbp) as the short arm of the targeting vector. 
  Embryonic stem (ES) cell cultures and gene-targeting experiments were carried out 
as previously described. Targeted ES cells were microinjected into 129/Sv blastocysts. 
DNA was extracted from the biopsied tail of mouse pups, and the F1 generation of the 
mutant animals was identified by Southern blot analysis with a 3’ external probe which 





The heterozygous mice were crossbred with EIIa-Cre transgenic mice to remove the 
pgk-neo gene, after which the generated PS1-R278I knockin mice were backcrossed to 
the C57BL6/J strain. When the pgk-neo gene was removed by the cre-loxP system, a 
short sequence ranging from the EcoRI to the SmaI sites of intron 7 was also removed. 
Deletion of such a short sequence in intron 7 leads to feasible detection of the genotype 
of mutant mice. To genotype the PS1-R278I knockin mouse, tail DNA was isolated and 
subjected to PCR analysis using the following primer sets: 
5’-AGTTTCAGACCAGCCTAGGCCAC-3’ and 
5’-AGGAAGGGAGACTTGACAGC-3’. 
Other mutant mice 
PS1 knockout mice and PS1-M146V knockin mice were purchased from the Jackson 
Laboratory. APP23 mice carrying the human APP695 transgene harboring the Swedish 
mutation (KM670/671NL)43 have been described previously44. All animal experiments 
were carried out according to the RIKEN Brain Science Institute’s guidelines for animal 
experimentation. 
Mouse embryonic fibroblasts (MEFs) 
MEFs were prepared from E13-14 embryos of wild-type, PS1-R278I knockin and PS1 
knockout mice, and inoculated in Dulbecco’s modified Eagle’s medium supplemented 
with 10% fetal bovine serum. The conditioned medium and cell lysates from MEFs 
(passage <8) were subjected to biochemical analyses, including ELISA, native-PAGE 
and Western blotting. Transfection of the MEFs with the Myc-tagged ΔNotch 
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construct45 was performed using FuGENE 6 Transfection Reagent (Roche) according to 
the manufacturer’s instructions. 
Blue native-polyacrylamide gel electrophoresis (BN-PAGE) 
Non-denaturing native PAGE was performed to confirm the integrity of the γ-secretase
complexes17 using the Novex Bis-Tris gel system (Invitrogen) according to the 
manufacturer’s instructions. Samples were extracted from embryonic brains and MEFs 
using the sample buffer from the Novex Bis-Tris gel system that contains 1% digitonin. 
Equal amounts of proteins as determined using the BCA Protein Assay Kit (Pierce) 
were loaded on a 3-12% gradient Bis-Tris acrylamide gel. Immunoblotting was 
performed using H70 (anti-PS1 N-terminal antibody, Santa Cruz) and Ab-2 (anti-PS2 
antibody, Calbiochem) antibodies. 
Immunoprecipitation assay and Western blot analysis 
Brain homogenates from embryonic brains (E14-16) and cell lysates of MEFs were 
immunoprecipitated with H70, and then captured by Dynabead conjugating protein G 
(Invitrogen). Immunoprecipitants were subjected to Western blot analysis using H70, 
MAB5232 (anti-PS1-Loop antibody, Chemicon), Ab-2, PA1-758 (anti-Nicastrin 
antibody, Affinity Bioreagents), anti-Pen-2 (Zymed), and ACS-01 (anti-Aph1 
antibody)10 antibodies. The following antibodies were also used in Western blot 
analysis: 6E10 (anti-Aβ1-12 antibody, Covance), 22C11 (anti-APP-N-terminal 
antibody, Chemicon), anti-APP-CTF antibody (Sigma), 9B11 (anti-Myc antibody, Cell 




Enzyme-linked immunosorbent assay (ELISA) 
Soluble materials from mouse cortical hemispheres were dissolved in Tris-HCl buffered 
saline (TS fraction) and the insoluble materials were dissolved in guanidine-HCl 
solution (GuHCl fraction) as previously described46. Samples from the brains and from 
the conditioned medium of MEFs were analyzed using an Aβ-ELISA kit (Wako) to 
quantify Aβ40. In order to specifically quantify the levels of Aβ42 and Aβ43, we 
established an Aβ42- and Aβ43-specific sandwich ELISA system utilizing the 
Aβ-ELISA kit (Wako). Since BC05, a detection antibody of this kit, cross-reacts with 
Aβ42 and Aβ43 as previously described47, we used the Aβ42- and Aβ43-specific
antibodies, C42 (anti-Aβ42 specific antibody, IBL) and C43 (anti-Aβ43 specific 
antibody, IBL). The specificities of these antibodies are shown in Fig.2c-e and 
Supplementary Fig. 6c-e. Samples were incubated overnight at 4 ºC in a 96-well plate 
coated with the capture antibody, BNT77 (anti-Aβ11-28 antibody48). Aβ from samples 
captured in the ELISA were incubated with C42 or C43 (1:100, for 3 hr at room 
temperature), respectively, after which HRP-conjugated anti-rabbit IgG (1:500, for 2 hr 
at room temperature) was added as a detection antibody. Synthesized Aβ42 or Aβ43
peptide (Peptide Institute) was used for the preparation of a standard curve, and diluted 
with the diluents solutions provided in the kit. For consistency, when we quantified the 
amount of Aβ40, a synthesized Aβ40 peptide (Peptide Institute) was also used for the 
preparation of a standard curve. This system also worked in broader concentration range 
of Aβ42 and Aβ43 (Supplementary Fig. 6a,b). Furthermore, a high sensitive Aβ43
system, based on modified protocols, was established for the measurement of samples 
containing low amount of Aβ43, e.g. samples derived from non APP Tg mice and non 
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APP-overexpressing cells (Supplementary Fig. 7.)
Immunohistochemical and histochemical studies 
Paraffin-embedded mouse brain sections were immunostained with the following 
antibodies: 4G8 (anti-Aβ17-24 antibody, Covance), C40 (anti-Aβ40 specific antibody, 
IBL). C42, C43 and MAB3402 (anti-GFAP antibody, Chemicon), with or without 
tyramide signal amplification (PerkinElmer Life Sciences) as previously described46.
Quantification of immunoreactivity from brain sections were carried out using 
MetaMorph imaging software (Universal Imaging Corp.) as previously described46.
Y-maze test 
Mice were housed individually before transferring to the behavioral laboratory. They 
were kept during the behavioral analysis. The light condition was 12h:12h (lights on 
8:00). The laboratory was air-conditioned and maintained temperature and humidity 
within approximately 22-23 ºC and 50-55%. Food and water were freely available 
except during experimentation. Large tweezers were used to handle mice in order to 
avoid individual differences in the handling procedure. All of the experiments were 
conducted in the light phase (9:00-18:00), and the starting time of the experiments was 
kept constant.  
The Y-maze apparatus (O’Hara, Tokyo, Japan) was made of gray plastic, and 
consisted of three compartments (3 cm (W) bottom and 10 cm (W) top, 40 cm (L) and 
12 cm (H)) radiating out from the center platform (3 x 3 x 3 cm triangle). The maze was 
positioned 80 cm above the floor, surrounded by a number of desks and test apparatuses 
around the maze to act as spatial cues. In this test, each mouse was placed in the center 
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of the maze facing towards one of the arms, and was then allowed to explore freely for 
5 min. Experiments were performed at a light intensity of 150 lux at the platform. An 
arm entry was defined as four legs entering one of the arms, and the experimenter 
counted the sequence of entries by watching a TV monitor behind a partition. An 
alternation was defined as entry into all three arms on consecutive choices (the 
maximum number of alternations was the total number of entries minus 2). The percent 
alternation was calculated as (actual alternations/maximum alternations) x 100. The 
percent alternation was designated as the spontaneous alternation behavior of the mouse, 
was taken as a measure of memory performance. 
Thioflavin T binding assay 
The thioflavin T binding assay was performed by mixing aliquots of Aβ. Amyloid 
β-protein (human, 1-40), amyloid β-protein (human, 1-42), and amyloid β-protein 
(human, 1-43) were purchased from the Peptide Institute. We first examined 
aggregation property of individual Aβ40, Aβ42 and Aβ43 by incubating the peptide 
separately at 20 μM in 50 mM potassium phosphate buffer (PPB) (pH 7.4) at 37 ºC for 
24 hrs with agitation. The stoichiometric effect of different Aβ species on aggregation 
was investigated in the mixture of Aβ40 and Aβ42 by adding and mixing Aβs in 50 mM 
PPB (pH 7.4) at molar concentrations of 20 μM : 2 μM : 0.2 μM (Aβ40 : Aβ42 : 
Aβ40/Aβ42/Aβ43 = 100 : 10 : 1) and incubating them at 37 ºC for 24 hrs with agitation. 
After incubation, thioflavin T was added to a final concentration of 5 μM, and thioflavin 
T fluorescence was measured at excitation and emission wavelengths of 442 nm and 
485 nm were used, respectively. 
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Neural cell toxicity assay 
Primary cortical neurons were isolated as previously described23 and plated at a density 
of 5 x 104 cells/well in 96 well plate (n = 6 wells in each experimental conditions). Day 
in vitro (DIV) 10 to DIV14 cultures were treated with synthesized Aβ40, Aβ42 and 
Aβ43 peptide (Peptide Institute) at 0.1 to 10 μM of Aβs for 72 hr. These Aβ peptides 
were dissolved in 10% (v/v) of 60 mM NaOH and 90% (v/v) of 10 mM phosphate 
buffer, pH7.4, which was used as the vehicle33. SH-SY5Y cells were plated at a density 
of 2 x 104 cells/well with 10% fetal bovine serum (FBS) supplemented medium in 96 
well plate (n = 6 wells in each experimental conditions), and incubated for 24 hr. Then, 
the media was replaced with media containing 1% of FBS, and treated with each Aβ
peptides for 48 hr. Cell viability was determined using MTS assay (CellTiter96 Aqueous 
One Solution Cell Proliferation Assay Kit: Promega)49, and LDH release as cell toxicity 
was performed using CytoTox-ONE Homogeneous Membrane Integrity Assay Kit 
(Promega)33, according to the manufacturer’s instructions and compared to vehicle 
treated cells, respectively. 
AD brain sections 
Postmortem AD brain tissues were kindly provided by J.Q. Trojanowski and V.M.-Y. 
Lee (University of Pennsylvania, Philadelphia, PA). The tissues had been fixed with 
ethanol or formalin and embedded in paraffin. This study was approved by the 
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